Low Molecular Weight Heparin Calcium Injection

Low molecular weight heparin calcium has obvious anti-coagulation factor Xa activity, and low anti-coagulation factor IIa or antithrombin activity (30IU/ml). Pharmacodynamic studies have shown that low molecular weight heparin calcium can inhibit the formation of thrombi and arteriovenous thrombi in vivo and in vitro, but does not affect platelet aggregation and the binding of fibrinogen to platelets. When playing an antithrombotic role, the possibility of bleeding is small. At the recommended dose for different indications, low molecular weight heparin does not prolong bleeding time. At the preventive dose, it does not significantly change APTT. The LD50 values of this product for subcutaneous injection and tail vein injection in mice are 3764mg/kg and 1655mg/kg, respectively.

The main ingredient of this product is low molecular weight heparin calcium, which is a calcium salt of aminodextran (heparin) fragment obtained from the intestinal mucosa.

This product is mainly used to prevent blood clot formation during hemodialysis and can also be used to treat deep vein thrombosis.

This product cannot be used for intramuscular injection. In the prevention and treatment of thromboembolic diseases, this product should be injected subcutaneously. To prevent blood clot formation during hemodialysis, a single dose of low molecular weight heparin calcium should be given from the arterial end at the beginning of each hemodialysis. The usual injection site for subcutaneous injection is the anterior and lateral abdominal wall, alternating left and right. The needle should enter the pinched skin fold vertically rather than obliquely. Use the thumb and index finger to pinch the skin fold until the injection is completed. 1 Treatment of deep vein thrombosis: The dosage is 85IU/kg each time, twice a day, subcutaneously, 12 hours apart. Depending on the patient's weight range, it can be injected once every 12 hours at a dose of 0.1ml/10kg. Note: For patients weighing more than 100kg or less than 40kg, it is difficult to estimate the dosage, and insufficient low molecular weight heparin dosage or bleeding symptoms may occur. Clinical observation should be strengthened for these patients. The use of low molecular weight heparin should not exceed 10 days. Unless there are contraindications, oral anticoagulants should be given as soon as possible when starting treatment. This product should be used for treatment until the INR index is reached. The platelet count should be monitored during the treatment with this product; 2. Prevention of blood clot formation during hemodialysis: The optimal dose should be selected considering the patient's condition and hemodialysis technical conditions. A single dose of low molecular weight heparin 4100AXaIU should be given from the arterial end at the beginning of each hemodialysis or as directed by the doctor. For patients at risk of bleeding during hemodialysis, the dosage of low molecular weight heparin calcium can be half of the recommended dose. If the hemodialysis time exceeds 4 hours, a small dose of low molecular weight heparin calcium can be given during hemodialysis, and the subsequent dose used for hemodialysis should be adjusted according to the effect observed during the initial hemodialysis.

As with other heparin preparations, bleeding manifestations at different sites occur mostly in patients with other risk factors (see Contraindications and Drug Interactions). Occasionally, thrombocytopenia and occasional thrombosis have been reported (see Special Warnings). Skin necrosis has occurred in a very small number of patients during heparin and low molecular weight heparin treatment, usually at the injection site, with the precursor manifestation of purpura, infiltration or painful erythema, with or without clinical symptoms. If skin necrosis occurs, the drug should be discontinued immediately. Occasionally, small hematomas and hard nodules may occur at the injection site, but they do not indicate heparin encapsulation, and these nodules usually disappear after a few days. Skin reactions Eosinophilia that can be recovered after discontinuation of the drug Systemic allergic reactions, including angioedema Transient increase in transaminases In very rare cases, priapism and reversible hyperkalemia related to heparin-induced aldosterone suppression have occurred, especially in high-risk patients.

Allergic to this product: history of thrombocytopenia caused by low molecular weight heparin calcium, bleeding signs or bleeding risks related to coagulation disorders, excluding non-heparin-induced disseminated intravascular coagulation, organic lesions prone to bleeding, accidental cerebrovascular hemorrhage, and acute bacterial endocarditis.

Due to the possible increased risk of bleeding, it is not recommended to be used in combination with aspirin (or other salicylates) or nonsteroidal anti-inflammatory drugs and other antiplatelet drugs. If combined use is necessary, close clinical and biological monitoring should be carried out. Low molecular weight heparin calcium should be used with caution in patients taking oral anticoagulants, glucocorticoids and dextran. For patients who have already used low molecular weight heparin calcium and use oral anticoagulants, low molecular weight heparin calcium treatment should be continued until the INR is stable. Incompatibility: cannot be mixed with other preparations.

Keep tightly closed in a cool place.

0.4ml:4100AXaIU

Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

• Founded in:

  2000-09-28

• Address:

  No. 71, Menglong Street, South District, Zhengding County High-tech Industrial Development Zone, Zhengding Area, China (Hebei) Pilot Free Trade Zone

• Tax NO.:

  91130100732914772Y

• Registered Funds:

  919.060878 yuan

• Website:

  Log in to view

• Email:

  Log in to view